SCHEMBL25370754

SCHEMBL25370754

O=C(O)CCOCCOCCNC(=O)CCNC(=O)OCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
HTT P42858 1/20 0.61
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
L3MBTL1 Q9Y468 3/20 0.51
MAPT P10636 1/20 0.50
FOLH1 Q04609 4/20 0.47
CPB1 P15086 1/20 0.46
GAA P10253 1/20 0.46
TGM2 P21980 1/20 0.46
PRSS1 P07477 1/20 0.46
TPSAB1 Q15661 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25330907 0.96 LMNA (0.74) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL18886422 0.94 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL18886394 0.94 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL16295008 0.94 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL31097862 0.94 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL30783527 0.94 SMN1; SMN2 (0.83) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL24038747 0.92 LMNA (0.76) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL24383283 0.92 SMN1; SMN2 (0.85) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL17841845 0.90 LMNA (0.68) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL25940649 0.89 SMN1; SMN2 (0.60) LMNASMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482527-B1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-04-08 EP disclosed
US-20250154288-A1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-05-15 US disclosed
EP-4482527-A1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-01-01 EP disclosed
CN-119136836-A Cytotoxic targeting chimeras for C-C chemokine receptor 2 expressing cells 葛兰素史克知识产权发展有限公司 2024-12-13 CN disclosed
WO-2023161874-A1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 WO disclosed
WO-2023161874-A1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154288-A1 CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS CCR2, CCRL2, CCR5 LMNA 3943/4885SMN1; SMN2 3560/4885HTT 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.